March 3, 2026 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for treating cardiovascular and pulmonary diseases, recently reported late breaking echocardiography results from its Phase III clinical trial for ischemic heart failure of reduced ejection fraction (HFrEF), which affects millions of patients in the United States.
